Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | WDR5 | P61964 | 4/20 | 0.55 |
| ▸ | ACLY | P53396 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 3/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27908886 | 0.86 | TSHR (0.69) | NPC1TSHRWDR5ACLYMEN1 | |
| SCHEMBL4863945 | 0.80 | TSHR (0.60) | NPC1TSHRWDR5ACLYMEN1 | |
| SCHEMBL7572911 | 0.80 | NPC1 (1.00) | NPC1TSHRWDR5MEN1KMT2A | |
| SCHEMBL22005135 | 0.80 | HSP90AA1 (0.54) | NPC1TSHRWDR5ACLYMEN1 | |
| SCHEMBL7594909 | 0.79 | NPC1 (0.89) | NPC1TSHRWDR5MEN1KMT2A | |
| SCHEMBL3252007 | 0.78 | TSHR (0.58) | NPC1TSHRWDR5ACLYMEN1 | |
| SCHEMBL4865757 | 0.77 | TSHR (0.57) | NPC1TSHRWDR5ACLYMEN1 | |
| SCHEMBL23014188 | 0.77 | ALDH1A1 (0.71) | NPC1TSHRACLYMEN1KMT2A | |
| SCHEMBL22004398 | 0.76 | EIF2AK4 (0.51) | NPC1TSHRWDR5ALPL | |
| SCHEMBL2766570 | 0.76 | ERBB2 (0.68) | ACLYALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | NPC1 1013/4885TSHR 4803/4885WDR5 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.